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Background: The Kell blood group system expresses high and low frequency antigens with the most important in 
relation to transfusion including the antithetic KEL1 and KEL2; KEL3 and KEL4; KEL6 and KEL7 antigens. Kell 
is a clinically relevant system, as it is highly immunogenic and anti-KEL antibodies are associated with hemolytic 
transfusion reactions and hemolytic disease of the fetus and newborn. Although required in some situations, 
Kell antigen phenotyping is restricted due to technical limitations. In these cases, molecular approaches may 
be a solution. This study proposes three polymerase chain reaction genotyping protocols to analyze the single 
nucleotide polymorphisms responsible for six Kell antithetic antigens expressed in a Brazilian population.
Methods: DNA was extracted from 800 blood donor samples and three polymerase chain reaction-restriction 
fragment length polymorphism protocols were used to genotype the KEL*1/KEL*2, KEL*3/KEL*4 and 
KEL*6/KEL*7 alleles. KEL*3/KEL*4 and KEL*6/KEL*7 genotyping was standardized using the NlaIII 
and MnlI restriction enzymes and validated using sequencing. KEL*1/KEL*2 genotyping was performed using 
a previously reported assay.
Results: KEL genotyping was successfully implemented in the service; the following distribution of KEL alleles 
was obtained for a population from southeastern Brazil: KEL*1 (2.2%), KEL*2 (97.8%), KEL*3 (0.69%), 
KEL*4 (99.31%), KEL*6 (2.69%) and KEL*7 (97.31%). Additionally, two individuals with rare genotypes, 
KEL*1/KEL*1 and KEL*3/KEL*3, were identified.
Conclusion: KEL allele genotyping using these methods proved to be reliable and applicable to predict Kell 
antigen expressions in a Brazilian cohort. This easy and efficient strategy can be employed to provide safer 
transfusions and to help in rare donor screening.
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Introduction
The Kell blood group system is the third most polymorphic known to date and one of 
the most clinically relevant in respect to triggering immune reactions. The Kell blood group 
system comprises at least 36 antigens(1) that are carried on a single red-cell transmembrane 
protein of 93 kDa(2). Most of the amino acid residues responsible for displaying different 
Kell antigens are present in the non-conserved globular domain that is away from the plasma 
membrane. A few of the amino acid substitutions occur in the conserved domain but they are 
also on the protein surface(3). 
Some of Kell antigens are arranged in antithetical set pairs of high and low frequency 
antigens and others are independently expressed antigens, for which antithetical partners have 
not been found(4,5). The antithetical antigens include KEL1 (K, “Kell”) and KEL2 (k, “Cellano”); 
KEL3 (Kpa), KEL4 (Kpb) and KEL21 (Kpc); and KEL6 (Jsa) and KEL7 (Jsb)(5). KEL4, unlike 
the other high-prevalence antigens, is associated with two antithetical low-prevalence antigens, 
KEL3 and KEL21(6). Individuals who are negative for a high frequency antigen, including 
KEL:-2, KEL:-4 or KEL:-7, present rare phenotypes. Weakened Kell antigens may be found in 
individuals with absent XK protein expressions (McLeod phenotype) or some Gerbich-negative 
phenotypes(7,8). Another rare variant phenotype associated with the Kell blood group system is 
Ko(null), which lacks all Kell antigens and displays enhanced Kx antigens(9). 
The antigens are derived from single nucleotide polymorphisms (SNPs) in the KEL gene, 
which is located at 7q33 and contains 19 exons(10). KEL1 and KEL2 antigens result from a 
SNP (C578T) in exon 6 that produces a T193M amino acid change. KEL3 and KEL4 antigens 
result from a point mutation in exon 8 (C841T) that leads to a tryptophan in KEL3 instead of 
an arginine in KEL4 at amino acid position 281. KEL6 and KEL7 antigens are related to a 
SNP in exon 17 (T1790C) that encodes a proline in KEL6 or a leucine in KEL7(1). 
Antibodies against antigens in the Kell blood group system are usually immunoglobulin 
G, that can cause severe hemolytic transfusion reactions, as well as hemolytic disease of the 
fetus and newborn (HDFN). The most important is anti-KEL1, which is a clinically significant 
antibody. HDFN used to be most commonly associated to Rh alloimmunization, but the use of 
anti-RhD immunoglobulin as a prophylactic agent has decreased this, and, consequently, HDFN 
caused by anti-KEL is now more frequent. Anti-KEL1 currently accounts for approximately 
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10% of the cases of severe anemia in newborns(11). Furthermore, 
this antibody has already been reported in the induction of 
myelosuppression, which probably contributes to the anemia(12). 
Although observed at a much lower frequency, anti-KEL2(13), 
anti-KEL3(14), anti-KEL4(15), anti-KEL6(16) and anti-KEL7(17) have 
also been correlated with moderate to severe HDFN.
Antigen frequencies vary in populations from different 
ethnic backgrounds. Differences in the frequencies of red blood 
cell (RBC) antigens between European and African descendants 
have great importance in transfusion medicine, mainly in a 
multiethnic population. For example, a patient of African origin 
with a KEL:6,-7 phenotype may be transfused with blood from 
donors of European origin. As a result, this patient may produce 
anti-KEL7; when future transfusions are required in these cases, 
KEL:6,-7 RBCs are necessary(6,18,19). Even though the frequency of 
this phenotype is very low, the identification of KEL6 and KEL7 
may be difficult as there is a lack of commercial antibodies and 
specific and potent antisera are not readily available(20). Besides 
reagent limitations, phenotyping may also be impaired in other 
situations, such as when a patient has recently been transfused or 
has hemolytic anemia or when large-scale typing is required(21).
Considering the importance of Kell antigens in 
alloimmunization and the limitations of serologic methods, 
this study reports on the use of a previously reported assay for 
KEL*1/KEL*2 genotyping(22) and the development of polymerase 
chain reaction (PCR) restriction fragment length polymorphism 
(RFLP) techniques to KEL*3/KEL*4 and KEL*6/KEL*7 alleles. 
Methods
Blood samples and DNA extraction
Eight hundred blood samples were selected from volunteer 
blood donors at the Associação Beneficente de Coleta de Sangue 
(COLSAN). All donors gave their informed consent and 200-μL 
blood samples were used for DNA extraction with the DNA blood 
mini kit (QIAamp, Qiagen, Inc., Valencia, CA) following the 
manufacturer’s instructions. DNA concentration was estimated 
using the NanoDrop 2000 Spectrophotometer (Thermal Cycler, 
Uniscience Inc., São Paulo, SP, Brazil) and DNA samples were 
kept at -20°C for long-term storage. 
Polymerase chain reaction primer design and 
amplification
The KEL gene was selected in the ensemble database (http://
www.ensembl.org/index.html) and primers were designed using 
the Primer 3 program (http://frodo.wi.mit.edu/). Hairpin and 
autodimer formation were evaluated using Autodimerv1removal 
(http://www.cstl.nist.gov/biotech/strbase/AutoDimerHomepage/
AutoDimerProgramHomepage.htm)(23). Alleles, nucleotide 
changes and primer sequences are described in Table 1.
Polymerase chain reaction (PCR) was performed with 100 ng 
of DNA, 10 pmol of each primer, 5 nmol of each dNTP, 50 nmol of 
MgCl2, 1.0 U Taq DNA polymerase and buffer in a final volume of 
25 µL. The PCR sequence used in all assays was as follows: 15 
min at 95°C; 35 cycles of 30 s at 94°C, 30 s at 62°C and 30 s at 
72°C; followed by 10 min at 72°C.
Polymerase chain reaction-restriction fragment length 
polymorphism analysis
After amplification, 5 μL of PCR product was digested for 8 
hours at 37°C with the appropriate restriction enzyme, according 
to Table 1. Restriction enzyme digestion was performed in a 
final volume of 10 μL under the conditions recommended by the 
manufacturer. RFLP bands were analyzed after electrophoresis in 
2% agarose gel for KEL*1/KEL*2 and KEL*3/KEL*4 genotyping 
and in 4% agarose gel for KEL*6/KEL*7 genotyping. Gels were 
stained with GelRed™ nucleic acid gel stain (Biotium, Inc, 
Hayward, CA), 10,000x in water. 
Polymerase chain reaction-restriction fragment length 
polymorphism validation
To check the accuracy of the protocol used, ten DNA 
samples, previously genotyped by PCR-RFLP, were sequenced. 
PCR products amplified as described above were purified with 10 
units of exonuclease I and 1 unit of FastAP™ Thermosensitive 
Alkaline Phosphatase (Fermentas, Hanover, MD) at 37°C during 
45 min followed by heating inactivation of enzymes at 80°C for 
15 min. Purified PCR products were submitted to sequencing 
reaction that consisted of 3 µL of purified PCR product, 2 µL of 
Table 1 - Polymerase chain reaction-restriction fragment length polymorphism used to analyze three single nucleotide polymorphisms 
responsible for KEL1, KEL2, KEL3, KEL4, KEL6 and KEL7 expression
Alleles Nucleotide change Primer
Product 
Size (bp)
Restriction 
Enzyme Fragments Size (bp)
KEL*1/KEL*2 578C>T
Forward: 
5’-AAGCTTGGAGGCTGGCGCAT-3’ 156 Bsm I
KEL*1: 100, 56
Reverse: 
5’-CCTCACCTGGATGACTGGTG-3’ KEL*2: 156
KEL*3/KEL*4 841C>T
Forward: 
5’-AGGAGAAAAGCAGGGACCTC-3’ 364 Nla III
KEL*3: 159, 118, 87
Reverse: 
5’-AGGGGATGGAGTCAGAGACA-3’ KEL*4: 277, 87
KEL*6/KEL*7 1790T>C
Forward: 
5’-GTACCACCCACATCCTCACC-3’ 166 Mnl I
KEL*6: 102, 39, 24
Reverse: 
5’-ATGGAAAGGCAGCATAATGG-3’
KEL*7: 80, 39, 
22, 24
101
An easy and efficient strategy for KEL genotyping in a multiethnic population
Rev Bras Hematol Hemoter. 2013;35(2):99-102
BigDye Terminator v3.1 (Applied Biosystems, Foster City, CA) 
and an appropriate buffer. The reaction was submitted to 26 cycles 
at 96°C for 10 s, 50°C for 15 s and 60°C for 4 min. The product was 
purified using the BigDye X-terminator kit (Applied Biosystems) 
and sequencing analysis was performed in a 3500xL Genetic 
Analyzer (Applied Biosystems). Electropherograms were analyzed 
using sequencing analysis software (Applied Biosystems). 
Results
All three assays were standardized in order for them to be 
performed under the same cycling conditions to optimize time and 
equipment. It is important to note that digestion time is a critical 
point to avoid partial digestion that might lead to an incorrect 
result. PCR and RFLP products are shown in Figure 1. Genotyping 
was clearly identified, as the fragments are at a safe distance 
avoiding misinterpretation. Ten samples with different genotypes 
were sequenced to evaluate the efficiency of the protocol used. All 
results were compatible with PCR-RFLP (data not shown).
Allele frequencies are shown in Table 2. Of the 800 samples 
analyzed, the KEL2 allele frequency was 97.8% and one donor with 
the KEL*1/KEL*1 genotype was identified. A very high frequency 
of KEL*4 (99.31 %) was observed, however one donor with 
the rare KEL*3/KEL*3 genotype was also identified. Although the 
KEL*6 allele was present in a higher frequency of samples than 
KEL*3, no donor with the KEL*6/KEL*6 genotype was found. 
Discussion
By using PCR-RFLP, a conventional molecular technique, 
this study combined a previously reported assay to genotype 
KEL*1/KEL*2(22) with new genotyping assays for the identification 
of KEL*3/KEL*4 and KEL*6/KEL*7 to successfully analyze 
800 DNA samples. Besides reduced costs of PCR-RFLP, these 
protocols proved to be simple and it seems that any transfusion 
service, regardless of the size and complexity, could easily 
implement the technique.
Moreover, these new assays are consistent given that the 
results from PCR-RFLP analysis were confirmed by sequencing 
in all the ten subjects used for validating the technique. Through 
results obtained from the analysis of these three assays, the allele 
frequencies of the KEL1, KEL2, KEL3, KEL4, KEL5 and KEL6 
antigens were characterized in a Brazilian population. 
To the best of our knowledge, this is the first report of the 
frequencies of these alleles in a Brazilian population. The results 
of this study gave a lower frequency of KEL1 (2.2%) compared 
to English blood donors (9%). In contrast, the population of 
the current study presented a frequency of KEL1 higher than 
in Japanese (0.02%) and Black American populations (1.5%)
(18). Although investigated using different strategies, a very 
low incidence of KEL*3 (0.69%) was observed compared to a 
previous study that evaluated the frequency of KEL3 (2.28%) 
in almost 19,000 Caucasian individuals from Europe and North 
America using anti-KEL3(19). A higher frequency of KEL*6 
(2.69%) was observed in the current study compared to a 
Caucasian population that was found to be almost 100% negative 
for KEL6, however it was lower than studies with Afro-American 
individuals which reported a frequency of 19.5%(6). These results 
show the ethnic admixture in the Brazilian population, one of 
the most heterogeneous in the world, a characteristic attributed 
to the waves of immigration during the colonization process. 
The frequencies observed in this study reflect the presence of 
African genetic inheritance, with approximately 3.5 million 
Africans being introduced to Brazil due to the slave trade after 
the middle of the 15th century(24). It is essential to consider that the 
background of the Brazilian population is very distinct depending 
on the region of the country. The donors in this study are from the 
southeastern region of Brazil; a region that receives individuals 
from other regions of the country, especially from the Northeast. 
Thus, these results may show the mixed allele frequencies of the 
Brazilian population and not exclusively of this region.
It is also important to emphasize that the assay developed 
to identify KEL*6/KEL*7 is reliable because the SNP identified 
as 1790T>C was chosen for genotyping instead of the 2019A>G 
SNP. High-throughput RBC antigen genotyping assays use 
duplicate probes to detect the same allele with both SNPs, but 
Renoud et al.(25) demonstrated that probes recognizing KEL at 
2019 bp cannot be used to confirm KEL*6/KEL*7 genotyping 
results. These authors showed that in some Afro-American 
people the gene encoding the KEL7 antigen is different to the one 
that was originally described, presenting a cytosine at the 1790 bp 
position and guanine instead of an adenine in the 2019 position. 
Genotyping is an important tool in transfusion medicine and 
the development and implementation of molecular techniques in 
Table 2 - Presence and frequencies of KEL alleles in a 
Brazilian cohort
n %
KEL*1 35 2.20
KEL*2 1565 97.80
KEL*3 11 0.69
KEL*4 1589 99.31
KEL*6 43 2.69
KEL*7 1557 97.31
A B C
Figure 1 - polymerase chain reaction (PCR) restriction fragment length 
polymorphism (RFLP) electrophoresis gels
A. KEL*1/KEL*2 genotyping where sample in lane 1 was genotyped as 
KEL*1/KEL*2, in lane 2 as KEL*1/KEL*1, and in lane 3 as KEL*2/KEL*2
B. KEL*3/KEL*4 genotyping where sample in lane 4 was genotyped as 
KEL*4/KEL*4, in lane 5 as KEL*3/KEL*4, and in lane 6 as KEL*3/KEL*3
C. KEL*6/KEL*7 genotyping where sample in lane 7 was genotyped 
KEL*7/KEL*7 and in lane 8 as KEL*6/KEL*7
M identifies the 50 bp molecular marker and PCR identifies PCR products
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blood centers is essential to improve the service and to reduce 
limitations associated to conventional serology. Kell is an important 
blood group system and its genotyping allows the prediction of 
RBC phenotypes when the serology typing is impaired or when 
it is impossible due to the cost or lack of commercial antisera, 
as is the case with -KEL3, -KEL4, -KEL5, -KEL6 and -KEL7. 
Moreover, genotyping allows the identification of rare blood as this 
study found KEL*3/KEL*3and KEL*1/KEL*1 individuals, which 
may be useful when blood units are required for alloimmunized 
patients with anti-KEL1 and -KEL3 antigens.
Conclusion
DNA typing of Kell blood groups by PCR-RFLP using the 
assays described in this paper can contribute to the management 
of transfusions in alloimmunized patients by helping to identify 
antibodies and by allowing the identification of antigen-negative 
RBC units. This ensures more accurate selection of compatible 
donor units and is likely to prevent alloimmunization and reduce 
the incidence of hemolytic reactions. 
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